{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T18:00:50Z","timestamp":1775930450950,"version":"3.50.1"},"reference-count":24,"publisher":"Codon Publications","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergologia et Immunopathologia"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.aller.2013.07.005","type":"journal-article","created":{"date-parts":[[2013,10,26]],"date-time":"2013-10-26T11:45:20Z","timestamp":1382787920000},"page":"88-91","source":"Crossref","is-referenced-by-count":9,"title":["Cutaneous adverse reactions to lenalidomide"],"prefix":"10.15586","volume":"43","author":[{"given":"S.","family":"Imbesi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Allegra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Calapai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6228","reference":[{"key":"10.1016\/j.aller.2013.07.005_bib0005","doi-asserted-by":"crossref","first-page":"498342","DOI":"10.1155\/2012\/498342","article-title":"Lenalidomide in diffuse large B-cell lymphomas","volume":"2012","author":"Chiappella","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.aller.2013.07.005_bib0010","first-page":"253","article-title":"Lenalidomide for the treatment of relapsed and refractory multiple myeloma","volume":"4","author":"van de Donk","year":"2012","journal-title":"Cancer Manage Res"},{"key":"10.1016\/j.aller.2013.07.005_bib0015","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.aller.2013.07.005_bib0020","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.aller.2013.07.005_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.leu.2402745","article-title":"Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo","volume":"17","author":"Lentzsch","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.aller.2013.07.005_bib0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.aller.2013.07.005_bib0035","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.aller.2013.07.005_bib0040","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1208\/aapsj070103","article-title":"Properties of thalidomide and its analogues: implications for anticancer therapy","volume":"22","author":"Teo","year":"2005","journal-title":"AAPS J"},{"issue":"Suppl. 1","key":"10.1016\/j.aller.2013.07.005_bib0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12325-010-0102-x","article-title":"Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events","volume":"28","author":"P\u00e9rez Persona","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.aller.2013.07.005_bib0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","article-title":"Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens","volume":"11","author":"Zangari","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.aller.2013.07.005_bib0055","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aller.2013.07.005_bib0060","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.aller.2013.07.005_bib0065","first-page":"1298","article-title":"Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma","volume":"142","author":"Svigguni","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.aller.2013.07.005_bib0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2008.20.3737","article-title":"Erythema multiforme\/Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in lenalidomide-treated patients","volume":"27","author":"Castaneda","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.aller.2013.07.005_bib0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hon.1000","article-title":"Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options","volume":"30","author":"Allegra","year":"2012","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.aller.2013.07.005_bib0080","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00277-011-1235-y","article-title":"Stevens\u2013Johnson\/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation","volume":"91","author":"W\u00e4sch","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.aller.2013.07.005_bib0085","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3109\/0284186X.2012.732706","article-title":"Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy","volume":"52","author":"Musolino","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.aller.2013.07.005_bib0090","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00520-012-1481-0","article-title":"Lenalidomide cutaneous adverse event: a case of Stevens\u2013Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone","volume":"20","author":"Siniscalchi","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.aller.2013.07.005_bib0095","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1592\/phco.31.9.925","article-title":"Possible lenalidomide-induced Stevens\u2013Johnson syndrome during treatment for multiple myeloma","volume":"31","author":"Boruah","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.aller.2013.07.005_bib0100","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3109\/0284186X.2011.640347","article-title":"Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602","volume":"51","author":"Penna","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.aller.2013.07.005_bib0105","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00105-010-2121-6","article-title":"Papular drug eruption along the lines of Blaschko caused by lenalidomide","volume":"62","author":"Grape","year":"2011","journal-title":"Hautarzt"},{"key":"10.1016\/j.aller.2013.07.005_bib0110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archderm.142.2.198","article-title":"Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors","volume":"142","author":"Deng","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.aller.2013.07.005_bib0115","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2010.04.034","article-title":"Lenalidomide-induced purpuric eruption: a new adverse cutaneous reaction","volume":"65","author":"Kuohung","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.aller.2013.07.005_bib0120","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1161\/01.CIR.103.16.2102","article-title":"Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt\/endothelial nitric oxide synthase pathway","volume":"103","author":"Chavakis","year":"2001","journal-title":"Circulation"}],"container-title":["Allergologia et Immunopathologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054613002322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301054613002322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T17:01:45Z","timestamp":1688576505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301054613002322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0301054613002322"],"URL":"https:\/\/doi.org\/10.1016\/j.aller.2013.07.005","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}